Abstract
Background: Activins and inhibins are structurally related dimeric glycoprotein hormones belonging to the transforming growth factor-β superfamily but whether they are also involved in malignancy is far from clear. No study has reported the expression of INHBE in kidney cancer. The purpose of this study was to examine the expressions of INHBE in the tumor tissue of patients with clear-cell renal cell carcinoma (ccRCC) and to explore the pathologic significance. Methods: The INHBE mRNA expression in the tumor tissue of ccRCC patients was analyzed by using RNA sequencing data from the TCGA database. To examine the expression of inhibin βE protein, 241 ccRCC patients were recruited and immunohistochemistry was performed on the tumor tissue of these patients along with 39 normal renal samples. The association between the inhibin βE expression level and patient’s clinicopathological indices was evaluated. Results: In the normal renal tissue, inhibin βE was found to be expressed mainly by renal tubular epithelial cells. In the tumor tissue, inhibin βE was expressed mainly in cancer cells. The expressions of INHBE mRNA and protein in the tumor tissue of ccRCC patients increased significantly compared with those in normal renal samples. There was a significant correlation between the level of inhibin βE in the tumor tissue and tumor grade. Patients with a lower inhibin βE expression in the tumor tissue were found to have a longer overall survival and disease-specific survival. Conclusions: INHBE might be involved in the pathogenesis of ccRCC and function as a tumor promoter.
References
1.
Taneja
K
, Williamson
SR
. Updates in pathologic staging and histologic grading of renal cell carcinoma
. Surg Pathol Clin
. 2018
;11
(4
):797
–812
. .2.
Siegel
RL
, Miller
KD
, Jemal
A
. Cancer statistics, 2020
. CA Cancer J Clin
. 2020
;70
(1
):7
–30
.3.
Goyal
R
, Gersbach
E
, Yang
XJ
, Rohan
SM
. Differential diagnosis of renal tumors with clear cytoplasm: clinical relevance of renal tumor subclassification in the era of targeted therapies and personalized medicine
. Arch Pathol Lab Med
. 2013
;137
(4
):467
–80
. .4.
Hsieh
JJ
, Purdue
MP
, Signoretti
S
, Swanton
C
, Albiges
L
, Schmidinger
M
, Renal cell carcinoma
. Nat Rev Dis Primers
. 2017
;3
:17009
. .5.
Sepe
P
, Mennitto
A
, Corti
F
, Procopio
G
. Immunotherapeutic targets and therapy for renal cell carcinoma
. Immunotargets Ther
. 2020
;9
:273
–88
. .6.
De Maeseneer
DJ
, Delafontaine
B
, Rottey
S
. Checkpoint inhibition: new treatment options in urologic cancer
. Acta Clin Belg
. 2017
;72
(1
):24
–8
. .7.
Laird
M
, Glister
C
, Cheewasopit
W
, Satchell
LS
, Bicknell
AB
, Knight
PG
. “Free” inhibin α subunit is expressed by bovine ovarian theca cells and its knockdown suppresses androgen production
. Sci Rep
. 2019
;9
(1
):19793
. .8.
Bloise
E
, Ciarmela
P
, Dela Cruz
C
, Luisi
S
, Petraglia
F
, Reis
FM
. Activin A in mammalian physiology
. Physiol Rev
. 2019
;99
(1
):739
–80
. .9.
Frost
K
, Seir
K
, Lackner
A
, Grusch
M
, Grasl-Kraupp
B
, Schulte-Hermann
R
, Inhibin/activin expression in human and rodent liver: subunits α and βB as new players in human hepatocellular carcinoma?
Br J Cancer
. 2011
;104
(8
):1303
–12
.10.
Wacker
I
, Behrens
J
. Activin B antagonizes RhoA signaling to stimulate mesenchymal morphology and invasiveness of clear cell renal cell carcinomas
. PLoS One
. 2014
;9
(10
):e111276
. .11.
Ng
CF
, Xu
JY
, Li
MS
, Tsui
SK
. Identification of FHL2-regulated genes in liver by microarray and bioinformatics analysis
. J Cell Biochem
. 2014
;115
(4
):744
–53
. .12.
Lau
AL
, Kumar
TR
, Nishimori
K
, Bonadio
J
, Matzuk
MM
. Activin betaC and betaE genes are not essential for mouse liver growth, differentiation, and regeneration
. Mol Cell Biol
. 2000
;20
(16
):6127
–37
. .13.
Gingelmaier
A
, Brüning
A
, Kimmich
T
, Makovitzky
J
, Bergauer
F
, Schiessl
B
, Inhibin/activin-betaE subunit is expressed in normal and pathological human placental tissue including chorionic carcinoma cell lines
. Arch Gynecol Obstet
. 2011
;283
(2
):223
–30
. .14.
Vejda
S
, Erlach
N
, Peter
B
, Drucker
C
, Rossmanith
W
, Pohl
J
, Expression of activins C and E induces apoptosis in human and rat hepatoma cells
. Carcinogenesis
. 2003
;24
(11
):1801
–9
. .15.
Wada
W
, Medina
JJ
, Kuwano
H
, Kojima
I
. Comparison of the function of the beta(C) and beta(E) subunits of activin in AML12 hepatocytes
. Endocr J
. 2005
;52
(2
):169
–75
. .16.
Chabicovsky
M
, Herkner
K
, Rossmanith
W
. Overexpression of activin beta(C) or activin beta(E) in the mouse liver inhibits regenerative deoxyribonucleic acid synthesis of hepatic cells
. Endocrinology
. 2003
;144
(8
):3497
–504
. .17.
Lee
JI
, Dominy
JE
Jr, Sikalidis
AK
, Hirschberger
LL
, Wang
W
, Stipanuk
MH
. HepG2/C3A cells respond to cysteine deprivation by induction of the amino acid deprivation/integrated stress response pathway
. Physiol Genomics
. 2008
;33
(2
):218
–29
. .18.
Brüning
A
, Matsingou
C
, Brem
GJ
, Rahmeh
M
, Mylonas
I
. Inhibin beta E is upregulated by drug-induced endoplasmic reticulum stress as a transcriptional target gene of ATF4
. Toxicol Appl Pharmacol
. 2012
;264
(2
):300
–4
. .19.
Deli
A
, Kreidl
E
, Santifaller
S
, Trotter
B
, Seir
K
, Berger
W
, Activins and activin antagonists in hepatocellular carcinoma
. World J Gastroenterol
. 2008
;14
(11
):1699
–709
. .20.
Mylonas
I
, Matsingou
C
, Käufl
SD
, Brüning
A
. Inhibin/activin betaE-subunit in uterine endometrioid adenocarcinoma and endometrial cancer cell lines: from immunohistochemistry to clinical testing?
Gynecol Oncol
. 2011
;122
(1
):132
–40
. .21.
James
D
, Levine
AJ
, Besser
D
, Hemmati-Brivanlou
A
. TGFbeta/activin/nodal signaling is necessary for the maintenance of pluripotency in human embryonic stem cells
. Development
. 2005
;132
(6
):1273
–82
. .22.
Spitzhorn
LS
, Megges
M
, Wruck
W
, Rahman
MS
, Otte
J
, Degistirici
Ö
, Human iPSC-derived MSCs (iMSCs) from aged individuals acquire a rejuvenation signature
. Stem Cell Res Ther
. 2019
;10
(1
):100
. .23.
Makanji
Y
, Zhu
J
, Mishra
R
, Holmquist
C
, Wong
WP
, Schwartz
NB
, Inhibin at 90: from discovery to clinical application, a historical review
. Endocr Rev
. 2014
;35
(5
):747
–94
. .24.
Bergauer
F
, Brüning
A
, Shabani
N
, Blankenstein
T
, Jückstock
J
, Dian
D
, Inhibin/activin-betaE subunit in normal and malignant human cervical tissue and cervical cancer cell lines
. J Mol Histol
. 2009
;40
(5–6
):353
–9
. .25.
Sugiyama
M
, Kikuchi
A
, Misu
H
, Igawa
H
, Ashihara
M
, Kushima
Y
, Inhibin βE (INHBE) is a possible insulin resistance-associated hepatokine identified by comprehensive gene expression analysis in human liver biopsy samples
. PLoS One
. 2018
;13
(3
):e0194798
.26.
Hashimoto
O
, Funaba
M
, Sekiyama
K
, Doi
S
, Shindo
D
, Satoh
R
, Activin E controls energy homeostasis in both brown and white adipose tissues as a hepatokine
. Cell Rep
. 2018
;25
(5
):1193
–203
. .27.
Jückstock
J
, Kimmich
T
, Mylonas
I
, Friese
K
, Dian
D
. The inhibin-βC subunit is down-regulated, while inhibin-βE is up-regulated by interferon-β1a in Ishikawa carcinoma cell line
. Arch Gynecol Obstet
. 2013
;288
(4
):883
–8
. .28.
Kotulak-Chrzaszcz
A
, Klacz
J
, Matuszewski
M
, Kmiec
Z
, Wierzbicki
PM
. Expression of the Sonic Hedgehog pathway components in clear cell renal cell carcinoma
. Oncol Lett
. 2019
;18
(6
):5801
–10
. .29.
Morimoto
Y
, Kishida
T
, Kotani
SI
, Takayama
K
, Mazda
O
. Interferon-β signal may up-regulate PD-L1 expression through IRF9-dependent and independent pathways in lung cancer cells
. Biochem Biophys Res Commun
. 2018
;507
(1–4
):330
–6
. .30.
Fuertes
MB
, Woo
SR
, Burnett
B
, Fu
YX
, Gajewski
TF
. Type I interferon response and innate immune sensing of cancer
. Trends Immunol
. 2013
;34
(2
):67
–73
. .31.
Le Bon
A
, Etchart
N
, Rossmann
C
, Ashton
M
, Hou
S
, Gewert
D
, Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon
. Nat Immunol
. 2003
;4
(10
):1009
–15
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
